These results suggest that assessing PR intra‐tumor heterogeneity may enhance long‐term risk assessment for premenopausal breast cancer patients and could be valuable as an additional marker in clinical practice for personalized treatment strategies. The gene discussed is PGR; the disease is neoplasm.